Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.cmi.2020.07.020 http://scihub22266oqcxt.onion/10.1016/j.cmi.2020.07.020 32711057!7375961!32711057     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Clin+Microbiol+Infect 2020 ; 26 (11): 1520-1524 Nephropedia Template TP {{tp|p=32711057|t=2020. Viable SARS-CoV-2 in various specimens from COVID-19 patients |pdf=|usr=}}{{32711057}} gab.com Text Viable SARS-CoV-2 in various specimens from COVID-19 patients JO: Clin Microbiol Infect http://www.kidney.de/pget.php?&tw=1&pmid=32711057 #FOAvip OBJECTIVES: The aim was to determine whether various clinical specimens obtained from COVID-19 patients contain the infectious virus. METHODS: To demonstrate whether various clinical specimens contain the viable virus, we collected naso/oropharyngeal swabs and saliva, urine and stool samples from five COVID-19 patients and performed a quantitative polymerase chain reaction (qPCR) to assess viral load. Specimens positive with qPCR were subjected to virus isolation in Vero cells. We also used urine and stool samples to intranasally inoculate ferrets and evaluated the virus titres in nasal washes on 2, 4, 6 and 8 days post infection. RESULTS: SARS-CoV-2 RNA was detected in all naso/oropharyngeal swabs and saliva, urine and stool samples collected between days 8 and 30 of the clinical course. Notably, viral loads in urine, saliva and stool samples were almost equal to or higher than those in naso/oropharyngeal swabs (urine 1.08 +/- 0.16-2.09 +/- 0.85 log(10) copies/mL, saliva 1.07 +/- 0.34-1.65 +/- 0.46 log(10) copies/mL, stool 1.17 +/- 0.32 log(10) copies/mL, naso/oropharyngeal swabs 1.18 +/- 0.12-1.34 +/- 0.30 log(10) copies/mL). Further, viable SARS-CoV-2 was isolated from naso/oropharyngeal swabs and saliva of COVID-19 patients, as well as nasal washes of ferrets inoculated with patient urine or stool. DISCUSSION: Viable SARS-CoV-2 was demonstrated in saliva, urine and stool samples from COVID-19 patients up to days 11-15 of the clinical course. This result suggests that viable SARS-CoV-2 can be secreted in various clinical samples and respiratory specimens. Twit Text FOAVip Viable SARS-CoV-2 in various specimens from COVID-19 patients ????Clin Microbiol Infect http://www.kidney.de/pget.php?&tw=1&pmid=32711057 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32711057 #FOAvip English Wikipedia <ref>{{Cite pmid|32711057}}</ref> Viable SARS-CoV-2 in various specimens from COVID-19 patients #MMPMID32711057 Jeong HW; Kim SM; Kim HS; Kim YI; Kim JH; Cho JY; Kim SH; Kang H; Kim SG; Park SJ; Kim EH; Choi YK Clin Microbiol Infect 2020[Nov]; 26 (11): 1520-1524 PMID32711057show ga OBJECTIVES: The aim was to determine whether various clinical specimens obtained from COVID-19 patients contain the infectious virus. METHODS: To demonstrate whether various clinical specimens contain the viable virus, we collected naso/oropharyngeal swabs and saliva, urine and stool samples from five COVID-19 patients and performed a quantitative polymerase chain reaction (qPCR) to assess viral load. Specimens positive with qPCR were subjected to virus isolation in Vero cells. We also used urine and stool samples to intranasally inoculate ferrets and evaluated the virus titres in nasal washes on 2, 4, 6 and 8 days post infection. RESULTS: SARS-CoV-2 RNA was detected in all naso/oropharyngeal swabs and saliva, urine and stool samples collected between days 8 and 30 of the clinical course. Notably, viral loads in urine, saliva and stool samples were almost equal to or higher than those in naso/oropharyngeal swabs (urine 1.08 +/- 0.16-2.09 +/- 0.85 log(10) copies/mL, saliva 1.07 +/- 0.34-1.65 +/- 0.46 log(10) copies/mL, stool 1.17 +/- 0.32 log(10) copies/mL, naso/oropharyngeal swabs 1.18 +/- 0.12-1.34 +/- 0.30 log(10) copies/mL). Further, viable SARS-CoV-2 was isolated from naso/oropharyngeal swabs and saliva of COVID-19 patients, as well as nasal washes of ferrets inoculated with patient urine or stool. DISCUSSION: Viable SARS-CoV-2 was demonstrated in saliva, urine and stool samples from COVID-19 patients up to days 11-15 of the clinical course. This result suggests that viable SARS-CoV-2 can be secreted in various clinical samples and respiratory specimens. |Animals[MESH] |Betacoronavirus/genetics/isolation & purification/*physiology[MESH] |COVID-19[MESH] |Chlorocebus aethiops[MESH] |Coronavirus Infections/*virology[MESH] |Feces/virology[MESH] |Female[MESH] |Ferrets[MESH] |Genome, Viral/genetics[MESH] |Humans[MESH] |Male[MESH] |Microbial Viability[MESH] |Middle Aged[MESH] |Pandemics[MESH] |Pharynx/virology[MESH] |Pneumonia, Viral/*virology[MESH] |RNA, Viral/genetics[MESH] |SARS-CoV-2[MESH] |Saliva/virology[MESH] |Specimen Handling/*methods[MESH] |Urine/virology[MESH] |Vero Cells[MESH] |Viral Load[MESH]Viable SARS-CoV-2 in various specimens from COVID-19 patients (epmc).pdf DeepDyve Pubget Overpricing